Compare Gilead Sciences, Inc. (GILD) vs Li Auto Inc (LI) Price & Performance

Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.

The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.

Li Auto (LI) trades at $12.47, up 2.38% today, amid mixed technical signals with a bearish overall trend. The company reported declining revenue from $144.5B in 2024 to $112.3B in 2025, with net income dropping to $1.12B. Recent vehicle deliveries of 30,895 in June 2026 show ongoing operational activity despite competitive pressures in the EV market.

The outlook remains challenging with negative profit margins and high P/E ratio of 99.38, though analyst consensus targets $14.80. Key risks include intense competition and volatile earnings, while potential recovery hinges on successful execution of new models like the Li L8 launched in June 2026.